PMID- 24994780
OWN - NLM
STAT- MEDLINE
DCOM- 20150630
LR  - 20211122
IS  - 1745-7262 (Electronic)
IS  - 1008-682X (Print)
IS  - 1008-682X (Linking)
VI  - 16
IP  - 5
DP  - 2014 Sep-Oct
TI  - A population study of fasting time and serum prostate-specific antigen (PSA) 
      level.
PG  - 740-4
LID - 10.4103/1008-682X.125912 [doi]
AB  - Prostate cancer is one of the most common cancers in men. Traditional screening 
      and diagnostic methods include digital rectal examinations (DREs), biopsies and 
      serum prostate-specific antigen (PSA) tests, with the latter being the more 
      popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive 
      to external factors as well as other prostate diseases. As such, the reliability 
      of of the serum PSA level as a sole screening and diagnostic tool for prostate 
      cancer is controversial. Recently, it has been shown that fasting extremes can 
      affect concentrations of serum chemistry analytes, thus raising the question of 
      whether or not fasting has an effect on the highly sensitive PSA biomarker. 
      Patients testing for serum PSA levels are often concomitantly submitting to other 
      tests that require fasting, subjecting certain patients to a fasting PSA level 
      while others not. The objective of this study was to investigate whether this 
      discrepancy in fasting state translates into an effect on serum PSA levels. Serum 
      PSA levels and fasting time records for 157 276 men who underwent testing at 
      Calgary Laboratory Services (CLS; Calgary, Alberta, Canada) between 01 January 
      2010 and 31 March 2013 were accessed. Linear regression models of mean PSA levels 
      and fasting times revealed a statistically important relationship at certain 
      fasting times. Applying a dynamic mathematical model to explore the clinical 
      effect of fasting suggests minimal impact on serum PSA result interpretation. 
      Thus, patients can be tested for serum PSA levels regardless of their fasting 
      state.
FAU - Lau, Cheryl K
AU  - Lau CK
FAU - Guo, Maggie
AU  - Guo M
FAU - Viczko, Jeannine A
AU  - Viczko JA
FAU - Naugler, Christopher T
AU  - Naugler CT
AD  - Calgary Laboratory Services; Department of Pathology and Laboratory Medicine, 
      Department of Family Medicine, University of Calgary, Calgary, Canada.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Asian J Androl
JT  - Asian journal of andrology
JID - 100942132
RN  - EC 3.4.21.- (KLK3 protein, human)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - Asian J Androl. 2014 Sep-Oct;16(5):786; discussion 786. PMID: 25130470
MH  - Adult
MH  - Aged
MH  - Early Detection of Cancer/standards
MH  - Fasting/*blood
MH  - Humans
MH  - Kallikreins/*blood
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*blood
MH  - Reproducibility of Results
MH  - Time Factors
PMC - PMC4215671
EDAT- 2014/07/06 06:00
MHDA- 2015/07/01 06:00
PMCR- 2014/09/01
CRDT- 2014/07/05 06:00
PHST- 2014/07/05 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/07/01 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - 125912 [pii]
AID - AJA-16-740 [pii]
AID - 10.4103/1008-682X.125912 [doi]
PST - ppublish
SO  - Asian J Androl. 2014 Sep-Oct;16(5):740-4. doi: 10.4103/1008-682X.125912.